Stock Analysis on Net

Bristol-Myers Squibb Co. (NYSE:BMY)

$24.99

Selected Financial Data
since 2005

Microsoft Excel

Paying user area

The data is hidden behind: . Unhide it.

This is a one-time payment. There is no automatic renewal.


We accept:

Visa Mastercard American Express Maestro Discover JCB PayPal Google Pay
Visa Secure Mastercard Identity Check American Express SafeKey

Income Statement

Bristol-Myers Squibb Co., selected items from income statement, long-term trends

US$ in millions

Microsoft Excel

Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31), 10-K (reporting date: 2013-12-31), 10-K (reporting date: 2012-12-31), 10-K (reporting date: 2011-12-31), 10-K (reporting date: 2010-12-31), 10-K (reporting date: 2009-12-31), 10-K (reporting date: 2008-12-31), 10-K (reporting date: 2007-12-31), 10-K (reporting date: 2006-12-31), 10-K (reporting date: 2005-12-31).


The financial data indicates fluctuating trends in revenues and net earnings for the company over the analyzed years.

Revenues
Revenues showed an overall increasing trend from US$19,207 million in 2005 to a peak of US$46,518 million in 2020. This represents a substantial growth over the 15-year period. Revenues experienced some volatility, with notable decreases during 2007 to 2009, reaching a low point at US$15,879 million in 2014. However, from 2014 onwards, revenues recovered strongly, reaching a new high by 2020. The subsequent years showed revenues relatively stable, around the US$45,000 million mark, with minor fluctuations up to 2024.
Net earnings (loss) attributable to BMS
Net earnings exhibited considerable volatility and irregular patterns. After an initial decline from US$3,000 million in 2005 to US$1,585 million in 2006, net earnings fluctuated significantly, with a notable peak of US$10,612 million in 2009. Subsequent years saw net earnings decline sharply, including a marked loss of US$9,015 million in 2020. The following years showed recovery with positive earnings around US$6,000 to US$8,000 million in 2021 to 2023, but another loss of US$8,948 million occurred in 2024. This pattern suggests episodic substantial impairments or one-time charges impacting net earnings despite revenue growth.

In summary, while revenues have generally trended upwards over the two decades, net earnings have been subject to significant fluctuations, including both large profits and substantial losses. This indicates variability in profitability possibly due to factors such as cost management, investment activities, or extraordinary events affecting earnings independently of revenue performance.


Balance Sheet: Assets

Bristol-Myers Squibb Co., selected items from assets, long-term trends

US$ in millions

Microsoft Excel

Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31), 10-K (reporting date: 2013-12-31), 10-K (reporting date: 2012-12-31), 10-K (reporting date: 2011-12-31), 10-K (reporting date: 2010-12-31), 10-K (reporting date: 2009-12-31), 10-K (reporting date: 2008-12-31), 10-K (reporting date: 2007-12-31), 10-K (reporting date: 2006-12-31), 10-K (reporting date: 2005-12-31).


Current Assets

The current assets exhibit a fluctuating trend over the periods from 2005 to 2024. Initially, current assets decreased from approximately 12,283 million US dollars in 2005 to roughly 9,521 million in 2012, indicating a downward trend over these years. However, a recovery followed with notable increases starting in 2013, peaking significantly in 2019 at about 29,354 million US dollars. Subsequent years show some volatility but maintain relatively high levels compared to the earlier period, ending at 29,780 million in 2024. This pattern suggests periods of both contraction and expansion in liquid resources or assets expected to be converted into cash within a year, with a strong rebound post-2012 and sustained higher levels thereafter.

Total Assets

Total assets demonstrate an overall upward trend from 2005 through 2018, rising from approximately 28,138 million to roughly 34,986 million US dollars, indicative of gradual asset growth. A substantial increase is observed in 2019, where total assets surge dramatically to around 129,944 million, followed by a decline over the next years to about 92,603 million by 2024. This sharp spike and subsequent drop around 2019-2024 may reflect significant asset acquisitions, disposals, or other extraordinary events affecting the company's asset base. Despite the recent decline, total assets remain significantly elevated compared to the pre-2019 levels, suggesting a generally larger asset base in the more recent years.


Balance Sheet: Liabilities and Stockholders’ Equity

Bristol-Myers Squibb Co., selected items from liabilities and stockholders’ equity, long-term trends

US$ in millions

Microsoft Excel

Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31), 10-K (reporting date: 2013-12-31), 10-K (reporting date: 2012-12-31), 10-K (reporting date: 2011-12-31), 10-K (reporting date: 2010-12-31), 10-K (reporting date: 2009-12-31), 10-K (reporting date: 2008-12-31), 10-K (reporting date: 2007-12-31), 10-K (reporting date: 2006-12-31), 10-K (reporting date: 2005-12-31).


The analysis of the financial data reveals several significant trends in the company's liability and equity structure over the analyzed period.

Current Liabilities
Current liabilities exhibit fluctuations throughout the years. Initially, there was a decrease from 6,890 million USD in 2005 to 6,313 million USD in 2009, followed by gradual growth with some variability, peaking at 18,304 million USD in 2019. Since then, the values remain elevated, exceeding 22,000 million USD toward 2024, indicating an increase in the short-term obligations the company holds, particularly in the latter years.
Total Liabilities
Total liabilities show relative stability with modest growth in the earlier years, moving from 16,930 million USD in 2005 to a high of 23,356 million USD in 2013. From 2014 onward, there is a dramatic increase with an exceptional surge in 2019 reaching 78,246 million USD. After this peak, the total liabilities decrease gradually to around 65,674 million USD by 2023 before experiencing another increase in 2024. This pattern suggests a period of significant leveraging or large acquisitions followed by deleveraging.
Total Debt
Total debt trends align closely with total liabilities but on a smaller scale. The company reduced its total debt from 8,595 million USD in 2005 to approximately 5,445 million USD by 2010, followed by minor fluctuations through 2014. Beginning in 2015, the total debt jumps sharply, reaching 46,733 million USD and further increasing to nearly 50,649 million USD in 2024 after some fluctuation during 2021-2023. This escalation in debt corresponds with the peak and decline phases of total liabilities, indicating increased borrowing activity offset later by repayments or restructuring.
Total Shareholders’ Equity
Equity shows a steady increase from 11,208 million USD in 2005 up to 15,713 million USD in 2010, then fluctuates until 2017, with some decline evident in 2012 and a notable drop in 2017 to 11,741 million USD. Equity peaks significantly in 2019 at 51,598 million USD, coinciding with the peak in liabilities and debt, then experiences a sharp decline over the following years, dropping to 16,335 million USD by 2024. The surge and subsequent decline in equity alongside liabilities suggest significant financial restructuring or major transactions impacting owners’ capital.

Overall, the data indicates a period of considerable financial activity beginning around 2018-2019 characterized by increased borrowing and total liabilities, resulting in a substantial impact on shareholders’ equity. Post-2019, there is an observable partial reversal in these trends, although liabilities and debt remain historically elevated compared to the pre-2015 period, while equity shows a decreasing trend after the peak. These patterns reflect possible strategic financial adjustments, including leveraging for expansion or significant investment and subsequent periods of managing this elevated financial structure.


Cash Flow Statement

Bristol-Myers Squibb Co., selected items from cash flow statement, long-term trends

US$ in millions

Microsoft Excel

Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31), 10-K (reporting date: 2013-12-31), 10-K (reporting date: 2012-12-31), 10-K (reporting date: 2011-12-31), 10-K (reporting date: 2010-12-31), 10-K (reporting date: 2009-12-31), 10-K (reporting date: 2008-12-31), 10-K (reporting date: 2007-12-31), 10-K (reporting date: 2006-12-31), 10-K (reporting date: 2005-12-31).


The annual financial data reveals notable fluctuations and trends in the cash flow activities over the analyzed period.

Operating Activities
The net cash provided by operating activities generally exhibited an upward trajectory from 2005 through 2012, increasing from 1,836 million USD to a peak of 6,941 million USD in 2012. Following this, there was a sharp decline in 2013 to 3,545 million USD, with further dips observed until 2015 when the figure dropped to 1,832 million USD. After 2015, the cash from operating activities showed a strong recovery, reaching a new high of 16,207 million USD by 2021. Thereafter, a decline occurs through 2023, reaching 13,066 million USD, before modest growth resumes in 2024 with 15,190 million USD. Overall, operating cash flows demonstrate volatility but with a general pattern of growth and significant recovery post-2015.
Investing Activities
Net cash from investing activities displays considerable variability and predominantly negative flows in several years. Initial years such as 2005 and 2008 show positive cash inflows (1,191 million USD and 5,079 million USD respectively), but this was followed by sharp declines and negative values in subsequent years, for example, -4,380 million USD in 2009 and -6,727 million USD in 2012. The period from 2015 to 2024 is characterized by mostly negative cash flows, including substantial outlays of -9,770 million USD in 2015 and a steep decline to -21,352 million USD in 2024. This pattern suggests significant investments or asset purchases especially in the later years, reflecting strategic capital expenditure or acquisitions.
Financing Activities
Net cash provided by or used in financing activities generally trends negatively for most of the period, reflecting outflows such as debt repayments, dividend payments, or share repurchases. Values were mostly negative, with recurrent sizable outflows exceeding 3,000 million USD on several occasions (e.g., -3,637 million USD in 2005, -4,333 million USD in 2012). Exceptions to this trend occurred in 2019 and 2024 where positive net cash inflows were recorded—7,621 million USD and 5,127 million USD respectively—indicating possible capital raising or debt issuance during these years. Notably, after 2019's positive inflow, the financing cash flows reverted sharply negative in 2020 and 2021, with large outflows of -16,224 million USD and -16,962 million USD, followed by another reversal in 2024.
Overall Insights
Operating activities are the primary source of cash, showing resilience and recovery after downturns. Investing activities reflect heavy expenditures, particularly in recent years, possibly aligned with growth strategies or acquisitions. Financing activities indicate strategic shifts between capital raising and repayments, with sporadic periods of cash influx from financing sources. The interplay between these activities reveals an overall approach balancing operational cash generation with substantial investment commitments and financing adjustments to support the company’s financial strategy.

Per Share Data

Bristol-Myers Squibb Co., selected data per share, long-term trends

US$

Microsoft Excel

Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31), 10-K (reporting date: 2013-12-31), 10-K (reporting date: 2012-12-31), 10-K (reporting date: 2011-12-31), 10-K (reporting date: 2010-12-31), 10-K (reporting date: 2009-12-31), 10-K (reporting date: 2008-12-31), 10-K (reporting date: 2007-12-31), 10-K (reporting date: 2006-12-31), 10-K (reporting date: 2005-12-31).

1, 2, 3 Data adjusted for splits and stock dividends.


The analysis of the financial data over the indicated periods reveals several notable trends in earnings per share and dividend payments.

Basic Earnings per Share (EPS)

The basic EPS exhibited significant volatility across the years. Initial figures started modestly at 1.53 USD in 2005, dropped sharply to 0.81 USD in 2006, and then experienced a considerable increase, peaking at 5.35 USD in 2009. Post-2009, the EPS declined notably, reaching as low as 0.61 USD in 2017, interspersed with some recovery phases such as 2.67 USD in 2016 and 3.01 USD in 2018. Thereafter, fluctuations persisted with a sharp negative dip to -3.99 USD in 2020, rebounding again to positive values around 3 USD in subsequent years, and finally tumbling to -4.41 USD in 2024.

Diluted Earnings per Share (Diluted EPS)

The diluted EPS mirrored closely the basic EPS trends with nearly identical values each year. This congruence indicates minimal dilution effect from convertible securities or options within this timeframe. The same pattern of high volatility, peaks, and troughs was observed, including the peak at 5.34 USD in 2009 and significant negative values in 2020 and 2024.

Dividend per Share

Contrary to the earnings trends, dividends per share demonstrated a consistent and steady growth throughout the entire period. Beginning at 1.12 USD in 2005, dividends increased incrementally almost every year, reaching 2.42 USD by 2024. This steady dividend growth reflects a commitment to returning value to shareholders despite fluctuations in earnings, suggesting a focus on maintaining shareholder confidence and possibly reflecting stable cash flow management.

In summary, the data reveals a company with highly variable earnings per share, subject to earnings shocks or extraordinary events, especially evident in the years showing substantial positive and negative swings. Despite this, the policy for dividends has been stable and growth-oriented, indicating strategic prioritization of dividend consistency. Stakeholders might consider the volatility in earnings alongside the stable dividend trend when evaluating overall financial stability and shareholder value.